261 related articles for article (PubMed ID: 35056969)
1. CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials.
Zhang Z; Kuo JC; Yao S; Zhang C; Khan H; Lee RJ
Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056969
[TBL] [Abstract][Full Text] [Related]
2. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system.
Hanagata N
Int J Nanomedicine; 2012; 7():2181-95. PubMed ID: 22619554
[TBL] [Abstract][Full Text] [Related]
3. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
Yu C; An M; Li M; Liu H
Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation.
Jurk M; Vollmer J
BioDrugs; 2007; 21(6):387-401. PubMed ID: 18020622
[TBL] [Abstract][Full Text] [Related]
5. CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies.
Hanagata N
Int J Nanomedicine; 2017; 12():515-531. PubMed ID: 28144136
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 9 and 21 have different ligand recognition profiles and cooperatively mediate activity of CpG-oligodeoxynucleotides in zebrafish.
Yeh DW; Liu YL; Lo YC; Yuh CH; Yu GY; Lo JF; Luo Y; Xiang R; Chuang TH
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20711-6. PubMed ID: 24282308
[TBL] [Abstract][Full Text] [Related]
7. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
8. Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals.
Martinson JA; Tenorio AR; Montoya CJ; Al-Harthi L; Gichinga CN; Krieg AM; Baum LL; Landay AL
Immunology; 2007 Apr; 120(4):526-35. PubMed ID: 17343615
[TBL] [Abstract][Full Text] [Related]
9. Oligodeoxynucleotides ODN 2006 and M362 Exert Potent Adjuvant Effect through TLR-9/-6 Synergy to Exaggerate Mammaglobin-A Peptide Specific Cytotoxic CD8+T Lymphocyte Responses against Breast Cancer Cells.
Babaer D; Amara S; McAdory BS; Johnson O; Myles EL; Zent R; Rathmell JC; Tiriveedhi V
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31091800
[TBL] [Abstract][Full Text] [Related]
10. Single Stranded DNA Immune Modulators with Unmethylated CpG Motifs: Structure and Molecular Recognition by Toll-Like Receptor 9.
Fehér K
Curr Protein Pept Sci; 2019; 20(11):1060-1068. PubMed ID: 31470785
[TBL] [Abstract][Full Text] [Related]
11. Toll-Like Receptor 21 of Chicken and Duck Recognize a Broad Array of Immunostimulatory CpG-oligodeoxynucleotide Sequences.
Chuang YC; Tseng JC; Yang JX; Liu YL; Yeh DW; Lai CY; Yu GY; Hsu LC; Huang CM; Chuang TH
Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33147756
[TBL] [Abstract][Full Text] [Related]
12. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
13. Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21.
Lai CY; Yu GY; Luo Y; Xiang R; Chuang TH
Front Immunol; 2019; 10():179. PubMed ID: 30800129
[TBL] [Abstract][Full Text] [Related]
14. CpG-oligodeoxynucleotides developed for grouper toll-like receptor (TLR) 21s effectively activate mouse and human TLR9s mediated immune responses.
Yeh DW; Lai CY; Liu YL; Lu CH; Tseng PH; Yuh CH; Yu GY; Liu SJ; Leng CH; Chuang TH
Sci Rep; 2017 Dec; 7(1):17297. PubMed ID: 29229937
[TBL] [Abstract][Full Text] [Related]
15. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.
Hornung V; Rothenfusser S; Britsch S; Krug A; Jahrsdörfer B; Giese T; Endres S; Hartmann G
J Immunol; 2002 May; 168(9):4531-7. PubMed ID: 11970999
[TBL] [Abstract][Full Text] [Related]
16. Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity.
Peter M; Bode K; Lipford GB; Eberle F; Heeg K; Dalpke AH
Immunology; 2008 Jan; 123(1):118-28. PubMed ID: 17961163
[TBL] [Abstract][Full Text] [Related]
17. Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists.
Meng W; Yamazaki T; Nishida Y; Hanagata N
BMC Biotechnol; 2011 Sep; 11():88. PubMed ID: 21943407
[TBL] [Abstract][Full Text] [Related]
18. Common human Toll-like receptor 9 polymorphisms and haplotypes: association with atopy and functional relevance.
Berghöfer B; Frommer T; König IR; Ziegler A; Chakraborty T; Bein G; Hackstein H
Clin Exp Allergy; 2005 Sep; 35(9):1147-54. PubMed ID: 16164440
[TBL] [Abstract][Full Text] [Related]
19. Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.
Li T; Hua C; Yue W; Wu J; Lv X; Wei Q; Zhu S; Zang G; Cui J; Liu YJ; Chen J
Pharmacol Res; 2020 Nov; 161():105293. PubMed ID: 33176206
[TBL] [Abstract][Full Text] [Related]
20. Cooperation of Oligodeoxynucleotides and Synthetic Molecules as Enhanced Immune Modulators.
Nigar S; Shimosato T
Front Nutr; 2019; 6():140. PubMed ID: 31508424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
